Skip to main content
. Author manuscript; available in PMC: 2017 Sep 29.
Published in final edited form as: Nature. 2017 Feb 13;542(7642):479–483. doi: 10.1038/nature21076

Figure 2. LKB1-AMPK is required to balance glucose and energy metabolism in pre-B ALL.

Figure 2

a, b, Heatmap of metabolomics (n = 2 per group, each in triplicate; a) and Western blots (n = 4; b) of patient-derived leukemia samples. c, Glucose uptake and ATP levels during B→ myeloid reprogramming (n = 4). d, Fold change of pre-B ALL cells carrying GFP-tagged Cre following Lkb1-deletion upon reprogramming (n = 6). e, Viability of pre-B ALL cells following deletion of Lkb1 or Ampkα2 (n = 3 independent experiments). f, Kaplan-Meier analysis (Mantel-Cox log-rank test) of recipient mice (n = 7 per group) injected with pre-B ALL cells following 4-OHT-induced deletion of Lkb1 or Ampkα2 (24 h). g, Patient-derived pre-B ALL cells treated with BML275 as indicated or in combination with prednisolone (n = 3), assessed by Combination Index (CI). Data, mean (± s.d), assessed by two-tailed t-test (c) or two-way ANOVA (d, e). For gel source data, see Supplementary Fig. 1.